Android app on Google Play

UBS on U.S. Biotechnology - Updating Outlook on Covered Stocks (GILD, AMGN, BIIB, CELG, INCY, IDIX, VRTX, SGEN)

September 10, 2012 12:55 PM EDT Send to a Friend
Get Alerts GILD Hot Sheet
Price: $109.00 +1.34%

Rating Summary:
    22 Buy, 5 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 24 | Down: 14 | New: 52
Trade GILD Now!
Join SI Premium – FREE
UBS on U.S. Biotechnology - Updating Outlook on Covered Stocks

Analyst, Matthew Roden, said, "Despite significant outperformance of the biotech group YTD (+35% vs. S&P: +14%), we remain positive on the large cap group considering (1) reasonable valuation (15x 2013 EPS, slightly above the S&P despite its 14% EPS growth vs. S&P: 4%), and (2) meaningful catalysts in 2012."

Gilead Sciences (Nasdaq: GILD) remains a Top Pick in large cap, citing considerable catalysts. Roden upgrades Amgen (Nasdaq: AMGN) to a 'Buy', but downgrades Biogen (Nasdaq: BIIB) and Celgene (Nasdaq: CELG) to 'Neutral'

For the small-mid cap category, Incyte Corporation (Nasdaq: INCY) is a Top Pick, and the firm continues to like Idenix Pharma (Nasdaq: IDIX)(PT lowered to $10), Vertex (Nasdaq: VRTX)(PT raised to $66) and Seattle Genetics (Nasdaq: SGEN)(PT raised to $30)




You May Also Be Interested In


Related Categories

Analyst Comments, Analyst PT Change, Downgrades, Upgrades

Related Entities

UBS, Standard & Poor's

Add Your Comment